GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,599.00p
   
  • Change Today:
      15.50p
  • 52 Week High: 1,711.20
  • 52 Week Low: 1,316.00
  • Currency: UK Pounds
  • Shares Issued: 4,114.88m
  • Volume: 3,932,103
  • Market Cap: £65,797m
  • RiskGrade: 129

JP Morgan says 'pent-up' demand will be exhausted, stays 'overweight' on Tech and Healthcare

By Alexander Bueso

Date: Monday 13 Jul 2020

LONDON (ShareCast) - (Sharecast News) - Equity strategists at JP Morgan believe that second quarter corporate results on both sides of the Atlantic may come in ahead of analysts' forecasts, helped by the fact that estimates were at very depressed levels.
However, the apparent recovery in economic growth was at risk of as so-called 'pent-up demand' was exhausted, they argued.

In a research note sent to clients, Mislav Matejka said: "We believe that one needs to see continued acceleration in activity momentum in 2H, beyond just a technical bounce from depressed levels that we expected will be seen in May/June, and probably July, prints.

"We fear that this is unlikely to be achieved, activity momentum could stall after July, or even outright dip lower, as pent up demand is exhausted, COVID-19 and trade uncertainty lingers and labour market stabilization slows."

On a positive note, Matejka said that many JP Morgan sector analysts were indeed anticipating better-than-expected results.

And the recent improvement in Purchasing Managers Indices could see companies sound more upbeat around the near-term trends.

But again, "The better-than-feared results could lead to some, likely transitory, bounce in Cyclical stocks as they report, but we suspect that this will not last.

The headwinds for Cyclical stocks could turn out to be "especially strong" in the final quarter of 2020.

So too, any rally in Value stocks was likely to end up being faded.

"In contrast to largely pro-cyclical sell-side consensus, we stay bullish on Tech [(Overweight)], Healthcare [(Overweight)] and Utilities [(Overweight)] in particular, and expect them to remain the top performers."

The IBES consensus was for a 45% drop in second quarter S&P 500 earnings and a 59% drop in those of Stoxx 600 companies.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,599.00p
Change Today 15.50p
% Change 0.98 %
52 Week High 1,711.20
52 Week Low 1,316.00
Volume 3,932,103
Shares Issued 4,114.88m
Market Cap £65,797m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
78.09% below the market average78.09% below the market average78.09% below the market average78.09% below the market average78.09% below the market average
39.62% below the sector average39.62% below the sector average39.62% below the sector average39.62% below the sector average39.62% below the sector average
Price Trend
20.69% above the market average20.69% above the market average20.69% above the market average20.69% above the market average20.69% above the market average
71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average
Income
44.86% above the market average44.86% above the market average44.86% above the market average44.86% above the market average44.86% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
26.1% below the market average26.1% below the market average26.1% below the market average26.1% below the market average26.1% below the market average
40.54% above the sector average40.54% above the sector average40.54% above the sector average40.54% above the sector average40.54% above the sector average

What The Brokers Say

Strong Buy 8
Buy 5
Neutral 9
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 22-Feb-24 16-Nov-23
Paid 11-Apr-24 11-Jan-24
Amount 16.00p 14.00p

Trades for 19-Apr-2024

Time Volume / Share Price
16:36 1,500 @ 1,599.00p
16:36 195,925 @ 1,599.00p
16:35 2,009,907 @ 1,599.00p
16:35 2,234 @ 1,599.00p
16:35 1,509 @ 1,599.00p

GSK Key Personnel

CEO Emma Walmsley

Top of Page